Rigel Pharmaceuticals (NASDAQ:RIGL) is scheduled to be releasing its earnings data after the market closes on Tuesday, August 4th. Analysts expect Rigel Pharmaceuticals to post earnings of ($0.13) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.13 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.13. Rigel Pharmaceuticals had a negative return on equity of 40.15% and a negative net margin of 27.39%. The firm had revenue of $55.76 million during the quarter, compared to analyst estimates of $56.94 million. On average, analysts expect Rigel Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
RIGL opened at $2.30 on Friday. The business has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.03. Rigel Pharmaceuticals has a twelve month low of $1.23 and a twelve month high of $5.24. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.68 and a current ratio of 3.73. The firm has a market cap of $407.94 million, a P/E ratio of -14.38 and a beta of 1.26.
Rigel Pharmaceuticals Company Profile
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia.
Featured Article: What are some reasons analysts would give stocks a buy rating?
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.